Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors. Watch the full video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
What a good morning we have today
And another this morning
Fantastic update
Here we gooooo
Well done all holders
This will soon be £1 + - MMs seem short of stock offered 87p on a dummy.
Indeed it is, wait for more PIs to catch on ...
Huge huge huge news here!!
An acquisition which will add further to the current true valuation which is 676pence per share, lets round it up to circa 800p per share shall we?
Re-rate long overdue.
Does anyone know of the suitability of Elast-eon and other Aortech polymers for 3D-Printing? It seems that there is an ever increasing array of medical and other components where this technology and it's use is growing fast. I have looked around but can't find any information on this.
https://www.equitydevelopment.co.uk/edreader/?ltkn=[ID]&d=%3D%3DQM5YjM
Our valuation We combine the implied 9.8X sales multiple valuation of AorTech Royalty with the intrinsic risk-adjusted valuations of AorTech Vascular and AorTech Heart Valve. The valuations of later two divisions have be determined from comparative medical device transactions that have been discounted back to AorTech’s stage of development and further risk-adjusted.
After adding AorTech’s cash at the end of September 2019, we determine a valuation for the whole business of £99.2m or 676 pence per share.
The 2000 share sell at about 11am today, was my buy.
reporting of sales/buys seems iffy to me.
I thought we were on the road to success.... I could smell it.... Why the sudden drops?
Since late October we have seen a significant recovery to July 2018 Highs.
We are now at levels not seen in seven years.
It is looking like 2020 will be a great year for Aortech.
That tells you all you need to know about where this is heading.....so cheap MCAP wise currently.
From what I can gather, Medibrane is a private Israeli company but it has been twice invested in by a VC company for a minority interest. The direct investment is by another Israeli company called STI Laser which is involved in lasering of metal parts of medical devices. Seems to have business worldwide. STI Laser itself was last year acquired by Resonetics Inc, a US company in the medical devices space. Resonetics, in turn, was acquired in 2017 by Regatta Medical, an investor in medical companies set up in 2017 as a partnership between Robert Hance and GTCR which is an investor in various sectors.
The CEO (Robert Hance) of Regatta Medical is a veteran in cardiovascular areas, who spent many years at Abbott but also a short spell at the FDA.
Regatta/Resonetics seems to have a wide range of investments and potential areas of business being sought by them. Perhaps Medibrane can leverage its relatively new network to widen interest in the benefits and uses of Elasteon? The RNS CEO comment seemed to envisage such an aim.
I get the impression Israel is a leading centre in medical developments and I am not certain if Aortech have done deals there before rather than the US.
Its very big news and MCAP Should be much higher with how far this company have come in the past couple of years....primed!
400p was a conservative broker note too....this could be revised upwards.
£1 coming up very soon.
Massive breakout coming here..... Broker note of conservative 400p....and news like that...
https://twitter.com/AntMwah/status/1196165917585166347
Already getting 92p to sell.
Yep. PPl not cottoned on to it yet.
BIG news and with the Seller clear, this could do bags..... watch.
Licence agreement signed.